Jefferies expects Sun Pharma to leverage its existing field force to market this product and incremental spend will largely be towards promotion of the product. It forecasts that Deuruxolitinib can achieve sales of around USD 765 million in the US EU market by 2031.

Tags: Previous Next
Generated by Feedzy